Ailawadhi, S., Špička, I., Lu, J., Oriol, A., Ling, S., Schjesvold, F., Berkovits, A., Hus, M., Dimopoulos, M. A., Rajnics, P., Hungria, V., Custidiano, M. D. R., Parmar, G., Leleu, X. P., Buck, T. T., Minarik, J., Zhang, R., Semiond, D., Stefanova-Urena, M., Moreau, P. (2025). Isatuximab (Isa) subcutaneous (SC) via an on-body delivery system (OBDS) vs Isa intravenous (IV), plus pomalidomide and dexamethasone (Pd) in relapsed/refractory multiple myeloma (RRMM): Results of the randomized, non-inferiority, phase 3 IRAKLIA study.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.7506